Business
BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million
News Release April 25, 2025 BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million COPENHAGEN, DENMARK, April 25, 2025 (GLOBE NEWSWIRE) – BioPorto, an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today the completion of a directed share capital raise of 25,000,000 new shares at the market offer price of DKK 1.3402 per share raising gross proceeds of DKK 33,505,000 mil
About this update from Bioporto A/s
[{"type":"image","alt":"BioPorto A/S","displaySize":"","headline":null,"caption":"BioPorto A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XFhYiV2fxrmNbtDA3N3v_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8","width":300,"height":55}},"lazy":false},{"type":"text","content":"News Release","length":12,"tagName":"p"},{"type":"text","content":"April 25, 2025","length":14,"tagName":"p"},{"type":"text","content":"BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million","length":118,"tagName":"p"},{"type":"text","content":"COPENHAGEN, DENMARK, April 25, 2025 (GLOBE NEWSWIRE) – BioPorto, an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today the completion of a directed share capital raise of 25,000,000 new shares at the market offer price of DKK 1.3402 per share raising gross proceeds of DKK 33,505,000 million.","length":358,"tagName":"p"},{"type":"text","content":"Jens Due Olsen, Chair of the Board, says: “I am pleased to have been elected as Chair of the Board of BioPorto. The capital raise will help the company reach its objective of advancing the commercial launch of ProNephro AKI NGAL in the US and with the preparation to apply for FDA clearance of the test for adult use. I look forward contributing to this journey.","length":362,"tagName":"p"},{"type":"text","content":"We thank our investors for the continuous support and welcome new investors who recognize the potential of our company.","length":119,"tagName":"p"},{"type":"text","content":"In addition, I take note of the participation in the private placement from BioPorto’s management team and the Board of Directors. This demonstrates continued commitment and belief in our mission to transform the landscape of AKI testing and care. By equipping clinicians with tools to detect AKI at an earlier stage, we aim to not only to save lives but also improve overall quality of life for patients affected by this condition.”","length":433,"tagName":"p"},{"type":"text","content":"To receive BioPorto’s Company Announcements, Press...